Biomx INC Form 4 insider transactions

BiomX Inc. director and 10% owner Reuven Yeganeh reported converting preferred stock into common shares and subsequently selling common stock and warrants in private transactions.

James E. Flynn, a director by deputization of BiomX Inc., reports the acquisition of warrants exercisable for 1,611,864 shares of common stock after stockholder approval was obtained.

Gregory Louis Merril, a director of BiomX Inc., filed an amended Form 4 to correct an administrative error in the reporting of derivative securities acquired.

Merav Bassan, Chief Development Officer of BiomX Inc., reports acquisition of restricted stock units and stock options in an amended SEC filing.

BiomX Inc. CEO Jonathan Solomon received 126,748 Restricted Stock Units and options to purchase 380,500 shares of common stock, according to a Form 4/A filing.

A BiomX Inc. director, Jesse Goodman, filed an amended Form 4 to correct an administrative error in the reporting of derivative securities acquired.

Director Eddie Williams files an amended Form 4 to correct an administrative error in reporting the acquisition of common stock options.

Alan Charles Moses, a director at BiomX Inc., filed an amended Form 4 to correct a reporting error regarding the acquisition of derivative securities.

Jonathan Leff, a director at BiomX Inc., files an amended Form 4 to correct an error in reporting the acquisition of derivative securities.

Susan Blum, a director at BiomX Inc., filed an amended Form 4 to correct an error in reporting the acquisition of common stock options.

Director Russell Greig files an amended Form 4 to correct a reporting error regarding the acquisition of derivative securities (options) in BiomX Inc.

BiomX CFO Marina Wolfson received stock options and restricted stock units, according to a Form 4/A filing with the SEC.

James E. Flynn, a director by deputization of BiomX Inc., reports the acquisition of stock options through Deerfield Management Company, L.P.

Marina Wolfson, CFO of BiomX Inc., reports the acquisition of restricted stock units and stock options.

Director Russell Greig acquired options to purchase 35,200 shares of BiomX Inc. common stock on April 14, 2025.

Director Gregory Louis Merril reports acquisition of options to purchase 17,600 shares of BiomX Inc. common stock.

Director Jonathan Leff reports acquisition of BiomX Inc. options, but disclaims beneficial ownership due to holding them for Deerfield Management Company, L.P.

Director Jesse Goodman reports acquisition of options to purchase 17,600 shares of BiomX Inc. common stock.

Merav Bassan, Chief Development Officer of BiomX Inc., reports the acquisition of restricted stock units and options, along with the disposal of common stock.

Director Eddie Williams reports acquisition of stock options in BiomX Inc. with a vesting schedule over four years.

Director Alan Charles Moses reports acquisition of options to purchase 17,600 shares of BiomX Inc. common stock.

BiomX Inc. CEO Jonathan Eitan Solomon reports the acquisition of stock options and restricted stock units (RSUs) in the company.

Director Susan Blum reports acquisition of options to purchase 17,600 shares of BiomX Inc. common stock.

The Cystic Fibrosis Foundation has filed a Form 4 indicating it no longer holds beneficial ownership of more than 10% of BiomX Inc.'s outstanding shares.

Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P. exercised warrants to acquire BiomX Inc. common stock at a reduced price, while also receiving new warrants and amending existing ones.

Merav Bassan, Chief Development Officer of BiomX Inc., reports the acquisition of 31,749 Restricted Stock Units (RSUs) that are immediately vested and convertible to common stock.

BiomX Inc. CEO Jonathan Eitan Solomon reports the acquisition of 50,556 Restricted Stock Units (RSUs) that are immediately vested and convertible to common stock.

Chief Business Officer of BiomX Inc., Assaf Oron, reports the acquisition of 25,804 Restricted Stock Units (RSUs) that convert into common stock.

Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P. converted Series X Preferred Stock into 5,883,000 shares of Common Stock each on July 15, 2024.

James E. Flynn, a director by deputization of BiomX Inc., reported the acquisition of stock options exercisable for 264,000 shares of common stock.